Clinical ResearchInterventional CardiologyPrognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Non–ST-Segment Elevation Myocardial Infarction Patients: ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) Platelet Substudy
Key Words
Abbreviations and Acronyms
Cited by (0)
This work was supported in part by Nycomed Pharma, Unterschleissheim, Germany (former distributor of bivalirudin in Europe), and a grant (KKF 04-06 [974404]) from Deutsches Herzzentrum, Munich, Germany. Material for platelet function testing was in part provided free of charge from Verum Diagnostica. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. Dr. Sibbing has received fees for advisory board activities from Verum Diagnostica and Eli Lilly; and speaker fees from AstraZeneca. Dr. Kastrati has received consulting fees from AstraZeneca, Bristol-Myers Squibb, and Daiichi Sankyo/Eli Lilly and lecture fees from Abbott, Biotronik, Cordis, and Medtronic. Dr. Mehilli has received lecture fees from Abbott, Daiichi Sankyo/Eli Lilly, and Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Sibbing and Bernlochner both contributed equally to this work.